

Competing interests statement:


Prof Rod Baber was commissioned by Healthed for this article. The ideas, opinions and information presented are solely those of the author. The advertiser does not necessarily endorse or support the views expressed in this article.

Prof Baber has been involved in the Speakers Bureau for Abbott and Besins. He is also on the Advisory Board for Pfizer.


Video Resources



Menopause Management Update
by Dr Elizabeth Farrell



Menopause Management Update
by Dr Sonia Davison



Menopause Management Update
by Bronwyn Stuckey



HRT and Breast Cancer
by Prof Peter Ebeling

Watch the full lectures on the Healthed website. Visit www.healthed.com.au/video

de Villiers TJ, Hall JE, Pinkerton JV, Pérez SC, Rees M, Yang C et al. *Revised global consensus statement on menopausal hormone therapy*. *Climacteric*. 2016(4); 19:313-5

Declaration

Prof Rod Baber was commissioned by Healthed for this article. The ideas, opinions and information presented are solely those of the author. The advertiser does not necessarily endorse or support the views expressed in this article.

The author competing interests statements can be viewed at www.healthed.com.au/monographs.

References

1. The Women's Health Initiative Study Group. *Design of the Women's Health Initiative Clinical Trial*. *Controlled Clin Trials*. 1998 Feb; 19(1): 61-109
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. *Risks and benefits of estrogen plus progestin in healthy post-menopausal women. Principal results from the Women's Health Initiative Randomised controlled trial*. *JAMA*. 2002 Jul; 288(3): 321-333

3. LaCroix AZ, Chlebowski RT, Manson JE, Johnson KC, Martin L, Margolis KL et al. *Health outcomes after stopping conjugated estrogens amongst postmenopausal women with prior hysterectomy*. *JAMA*. 2011 Apr; 305(13): 1305-1314. Available online at; <http://jamanetwork.com/journals/jama/fullarticle/896193>
4. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D et al. *Influence of estrogen plus progestin therapy on breast cancer and mammography in healthy post-menopausal women: the Women's Health Initiative Randomised controlled trial*. *JAMA*. 2003 Jun; 289(24): 3243-53
5. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH et al. *Estrogen plus progestin and breast cancer incidence and mortality in post-menopausal women*. *JAMA*. 2010 Oct; 304(15): 1684-1692. Available online at: <http://jamanetwork.com/journals/jama/fullarticle/186747>
6. Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL et al. *Prior hormone therapy and breast cancer risk in the Women's Health Initiative Randomised trial of estrogen plus progestin*. *Maturitas*. 2006 Sep; 55(2): 103-115

7. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL et al. *Menopausal hormone therapy and health outcomes during the intervention and post stopping phases of the Women's Health Initiative Randomised controlled trials.* JAMA. 2013 Oct; 310(13): 1353-1368
8. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. *Progestogens used in postmenopausal hormone therapy: Differences in their pharmacological properties, intracellular actions and clinical effects.* Endocr Rev. 2013 Apr; 34(2): 171-208
9. Judd HL, Mebane-Sims I, Legault C, Wasilauskas C, Johnson S, Merino M et al. *Effects of hormone replacement therapy on endometrial histology in postmenopausal women: The Postmenopausal Estrogen/Progestin Inverventions (PEPI) Trial.* JAMA. 1996 Feb; 275(5): 370-5
10. Stevenson JC, Hodis HN, Pickar JH, Lobo RA. *Coronary heart disease and menopause management: the swinging pendulum of HRT.* Atherosclerosis. 2009 Dec; 207(2): 336-340
11. Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM et al. *Venous thrombosis and conjugated equine estrogen in women without a uterus.* Arch Intern Med. 2006 Apr; 166(7): 772-780
12. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H et al. *Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative Randomised controlled trial.* JAMA. 2004 Apr; 291(14): 1701-1712. Available online at: <http://jamanetwork.com/journals/jama/fullarticle/198540>
13. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M et al. *Conjugated equine estrogens and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow up of the Women's Health Initiative Randomised trial.* Lancet Oncol. 2012 May; 13(5): 476-486
14. Schindler AE, Campagnoliu C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW et al. *A classification and pharmacology of progestins.* Maturitas. 2003 Dec; 46(S1): 7-16
15. Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M et al. *Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells.* Breast Cancer Res Treat. 2012 Jan; 131(1): 49-63
16. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. *Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort.* Int J Cancer. 2005 Apr; 114(3): 448-454
17. Asi N, Mohammed K, Haydour Q, Gionfriddo MR, Vargas OL, Prokop LJ et al. *Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis.* Syst Rev. 2016 Jul; 5(1): 121-9
18. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H et al. *Hormone therapy and venous thromboembolism among postmenopausal women.* Circulation. 2007 Feb; 115(7): 840-845. Available online at: <http://circ.ahajournals.org/content/115/7/840>
19. Canonico M, Fournier A, Carcaillon L, Olié V, Plu-Bureau G, Oger E et al. *Postmenopausal hormone therapy and risk of idiopathic venous thrombosis. Results from the E3N cohort study.* Arterioscler Thromb Vasc Biol. 2010 Feb; 30(2): 340-345. Available online at: <http://atvb.ahajournals.org/content/30/2/340>
20. Register TC, Adams MR, Golden DL, Clarkson TB. *Conjugated estrogens alone but not in combination with medroxyprogesterone inhibit aortic connective tissue remodelling.* Arterioscler Thromb Vasc Biol. 1998 Jul; 18(7): 1164-71. Available online at: <http://atvb.ahajournals.org/content/18/7/1164>
21. Simon JA. *What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead?* Menopause. 2014 Jul; 21(7): 769-83
22. Stute P, Neulen J, Wildt L. *The impact of micronized progesterone on the endometrium: a systematic review.* Climacteric. 2016 Aug; 19(4): 316-28
23. Darj E, Nilsson S, Axelsson O, Hellberg D. *Clinical and endometrial effects of estrogen and progesterone in postmenopausal women.* Maturitas. 1991 Jun; 13(2): 109-15
24. National Institute for Health and Care Excellence. *Menopause: diagnosis and management* [internet]. NICE. November 2015. Available online at: www.nice.org.uk/guidance/ng23
25. Baber R, Panay N, Fenton A, IMS Writing Group. *IMS Recommendations on midlife women's health and menopausal hormone therapy.* Climacteric. 2016 Apr; 19(2): 109-50
26. Stuenkel CA, Davis SR, Compel A, Lumsden MA, Murad MH, Pinkerton JV et al. *Treatments of symptoms of the menopause: An Endocrine Society clinical practice guideline.* J Clin Endocrinol Metab. 2015 Nov; 100(11): 3975-4011. Available online at: <https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2015-2236>
27. de Villiers TJ, Hall JE, Pinkerton JV, Pérez SC, Rees M, Yang C et al. *Revised global consensus statement on menopausal hormone therapy.* Climacteric. 2016(4); 19:313-5